 Two Phase 3-ready therapeutics Well capitalized to achieve clinical milestones Multiple USEU Orphan Drug and Fast Track designations What Kintara Therapeutics does: Kintara Therapeutics, Inc NASDAQ:KTRA is developing advanced cancer therapies for patients with rare unmet medical needs. The San Diego-based company is currently developing two Phase 3-ready therapeutics: VAL-083 for treating glioblastoma GBM, the most common and most aggressive form of primary brain cancer in adults and; REM-001 for treating cutaneous metastatic breast cancer CMBC. 